Ocular Therapeutix patent expiration

1. Dextenza patent expiration

DEXTENZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254267 OCULAR THERAPEUTIX Composite hydrogel drug delivery systems
Sep, 2024

(a month from now)

US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
Feb, 2030

(5 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
May, 2030

(5 years from now)

US11458041 OCULAR THERAPEUTIX Punctal plug and bioadhesives
Nov, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 30, 2021
New Indication(I-800) Jun 20, 2022
New Indication(I-876) Oct 07, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular inflammation and pain following ophthalmic surgery

Dosage: INSERT

More Information on Dosage

DEXTENZA family patents

Family Patents